Neobe Therapeutics is developing programmable engineered live biotherapeutics designed to remove physical and immunological barriers in the tumour microenvironment to enable immune cell infiltration. Its approach targets highly fibrotic stroma and other causes of immune exclusion that limit immunotherapy responses in solid tumours. Since inception the company has engineered two differentiated proprietary products with demonstrated pre-clinical efficacy aimed at colorectal, pancreatic and breast cancers. Neobe was founded in 2021 by CEO Pedro Correa de Sampaio and CSO Annelise Soulier out of a venture-creation alliance between Deep Science Ventures and Cancer Research Horizons. Leadership includes chair Keith Blundy, a serial BioMedTech executive with experience in drug development, strategy and VC fundraising. The company says the new funding and grant support will be used to advance its engineered live therapeutics toward clinical impact and broaden the benefits of immunotherapies to non-responding patients.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2024